High-Grade Glioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<h4><strong>Market Overview:</strong></h4>

<blockquote>
<p>The 7 major high-grade glioma markets are expected to exhibit a CAGR of 3.45% during 2024-2034.</p>
</blockquote>

<table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%">
<thead>
<tr>
<th scope="col" style="width:70%">
<div style="text-align:left">Report Attribute&nbsp;</div>
</th>
<th scope="col">
<div style="text-align:left">Key Statistics</div>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<div><strong>Base Year</strong></div>
</td>
<td>
<div>2023</div>
</td>
</tr>
<tr>
<td>
<div><strong>Forecast Years</strong></div>
</td>
<td>
<div>2024-2034</div>
</td>
</tr>
<tr>
<td>
<div><strong>Historical Years</strong></div>
</td>
<td>
<div>2018-2023</div>
</td>
</tr>
<tr>
<td><strong>Market Growth Rate 2024-2034</strong></td>
<td>3.45%</td>
</tr>
</tbody>
</table>

<p style="text-align:justify"><br />
The high-grade glioma market has been comprehensively analyzed in IMARC&#39;s new report titled <strong>&quot;High-Grade Glioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034&quot;.</strong> High-grade glioma refers to a type of malignant brain tumor that occurs in the glial cells, which are supportive cells in the central nervous system. This disease is considered the most severe and aggressive form of glioma. It is often characterized by rapidly dividing cancer cells, extensive infiltration into nearby brain tissues, and a high potential to spread to other parts of the brain. The symptoms of this ailment may vary depending on the tumor&#39;s location but commonly include headaches, seizures, cognitive decline, changes in personality, visual disturbances, mood swings, irritability, depression, weakness, paralysis, difficulty controlling movement in the limbs, a loss of sensation in certain areas of the body, etc. The diagnosis of high-grade gliomas typically involves a combination of a medical history review and a physical examination. A neurological assessment may be conducted to evaluate brain function and determine the potential impact of the tumor on various neurological abilities. The healthcare provider may further perform several diagnostic studies, such as magnetic resonance imaging (MRI), to visualize the brain and identify any abnormal growths.</p>

<p style="text-align:justify"><img alt="High-Grade Glioma Market" src="https://www.imarcgroup.com/CKEditor/ef98a7a6-d783-4285-a8db-e265790bf326high-grade-glioma-market.webp" style="height:450px; width:800px" /></p>

<p style="text-align:justify">The increasing cases of genetic mutations and inherited conditions, which alter proteins in ways that cause healthy tissues to become cancerous, are primarily driving the high-grade glioma market. In addition to this, the rising prevalence of immune system dysfunction, resulting in the proliferation of aberrant cells and the formation of tumors, is also creating a positive outlook for the market. Moreover, the widespread adoption of radiation therapy, since it involves the application of high-energy X-rays to kill tumors or prevent the progression of the disease, is further bolstering the market growth. Apart from this, the inflating utilization of anti-angiogenic drugs, like bevacizumab, that target vascular endothelial growth factor (VEGF) to inhibit the formation of abnormal blood vessels, thereby limiting the supply of nutrients and oxygen in tumors, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of stereotactic radiosurgery to treat recurrent disease conditions, owing to its several associated benefits, such as focused delivery, non-invasiveness, and reduced treatment duration, is expected to drive the high-grade glioma market during the forecast period.</p>

<p style="text-align:justify">IMARC Group&#39;s new report provides an exhaustive analysis of the high-grade glioma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for high-grade glioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the high-grade glioma market in any manner.</p>

<p><strong>Time Period of the Study</strong></p>

<ul>
<li>Base Year: 2023</li>
<li>Historical Period: 2018-2023</li>
<li>Market Forecast: 2024-2034<br />
&nbsp;</li>
</ul>

<p><strong>Countries Covered</strong></p>

<ul>
<li>United States</li>
<li>Germany</li>
<li>France</li>
<li>United Kingdom</li>
<li>Italy</li>
<li>Spain</li>
<li>Japan<br />
&nbsp;</li>
</ul>

<p><strong>Analysis Covered Across Each Country</strong></p>

<ul>
<li>Historical, current, and future epidemiology scenario</li>
<li>Historical, current, and future performance of the high-grade glioma market</li>
<li>Historical, current, and future performance of various therapeutic categories in the market</li>
<li>Sales of various drugs across the high-grade glioma market</li>
<li>Reimbursement scenario in the market</li>
<li>In-market and pipeline drugs</li>
</ul>

<h4><strong>Competitive Landscape:</strong></h4>

<p>This report also provides a detailed analysis of the current high-grade glioma marketed drugs and late-stage pipeline drugs.</p>

<p><strong>In-Market Drugs</strong></p>

<ul>
<li>Drug Overview</li>
<li>Mechanism of Action</li>
<li>Regulatory Status</li>
<li>Clinical Trial Results</li>
<li>Drug Uptake and Market Performance<br />
&nbsp;</li>
</ul>

<p><strong>Late-Stage Pipeline Drugs</strong></p>

<ul>
<li>Drug Overview</li>
<li>Mechanism of Action</li>
<li>Regulatory Status</li>
<li>Clinical Trial Results</li>
<li>Drug Uptake and Market Performance<br />
&nbsp;</li>
</ul>

<table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%">
<thead>
<tr>
<th scope="col" style="text-align:left; width:50%"><strong>Drugs</strong></th>
<th scope="col" style="text-align:left"><strong>Company Name</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gliadel wafer (Carmustine polifeprosan 20 wafer)</td>
<td>Arbor Pharmaceuticals/ Eisai</td>
</tr>
<tr>
<td>Avastin (Bevacizumab)</td>
<td>Genentech/Roche</td>
</tr>
<tr>
<td>Temodar (Temozolomide)</td>
<td>Merck &amp; Co</td>
</tr>
<tr>
<td>BMX001</td>
<td>BioMimetix</td>
</tr>
<tr>
<td>ONC201</td>
<td>Chimerix</td>
</tr>
<tr>
<td>LAM561</td>
<td>Laminar Pharmaceuticals</td>
</tr>
<tr>
<td>OS2966</td>
<td>OncoSynergy</td>
</tr>
<tr>
<td>PTC596</td>
<td>PTC Therapeutic</td>
</tr>
</tbody>
</table>

<p><br />
<strong>*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.</strong></p>

<h4><strong>Key Questions Answered in this Report:</strong></h4>

<p><strong>Market Insights</strong></p>

<ul>
<li>How has the high-grade glioma market performed so far and how will it perform in the coming years?</li>
<li>What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?</li>
<li>What was the country-wise size of the high-grade glioma market across the seven major markets in 2023 and what will it look like in 2034?</li>
<li>What is the growth rate of the high-grade glioma market across the seven major markets and what will be the expected growth over the next ten years?</li>
<li>What are the key unmet needs in the market?<br />
&nbsp;</li>
</ul>

<p><strong>Epidemiology Insights</strong></p>

<ul>
<li>What is the number of prevalent cases (2018-2034) of high-grade glioma across the seven major markets?</li>
<li>What is the number of prevalent cases (2018-2034) of high-grade glioma by age across the seven major markets?</li>
<li>What is the number of prevalent cases (2018-2034) of high-grade glioma by gender across the seven major markets?</li>
<li>How many patients are diagnosed (2018-2034) with high-grade glioma across the seven major markets?</li>
<li>What is the size of the high-grade glioma patient pool (2018-2023) across the seven major markets?</li>
<li>What would be the forecasted patient pool (2024-2034) across the seven major markets?</li>
<li>What are the key factors driving the epidemiological trend of high-grade glioma?</li>
<li>What will be the growth rate of patients across the seven major markets?<br />
&nbsp;</li>
</ul>

<p><strong>High-Grade Glioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies</strong></p>

<ul>
<li>What are the current marketed drugs and what are their market performance?</li>
<li>What are the key pipeline drugs and how are they expected to perform in the coming years?</li>
<li>How safe are the current marketed drugs and what are their efficacies?</li>
<li>How safe are the late-stage pipeline drugs and what are their efficacies?</li>
<li>What are the current treatment guidelines for high-grade glioma drugs across the seven major markets?</li>
<li>Who are the key companies in the market and what are their market shares?</li>
<li>What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the high-grade glioma market?</li>
<li>What are the key regulatory events related to the high-grade glioma market?</li>
<li>What is the structure of clinical trial landscape by status related to the high-grade glioma market?</li>
<li>What is the structure of clinical trial landscape by phase related to the high-grade glioma market?</li>
<li>What is the structure of clinical trial landscape by route of administration related to the high-grade glioma market?</li>
</ul>

<h4><strong>市场概述：</strong></h4>

<blockquote>
<p>预计到2034年，全球7个主要高级胶质瘤市场的复合年增长率（CAGR）将达到3.45%。</p>
</blockquote>

<table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%">
<thead>
<tr>
<th scope="col" style="width:70%">
<div style="text-align:left">报告属性</div>
</th>
<th scope="col">
<div style="text-align:left">关键统计数据</div>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>
<div><strong>基准年</strong></div>
</td>
<td>
<div>2023</div>
</td>
</tr>
<tr>
<td>
<div><strong>预测年份</strong></div>
</td>
<td>
<div>2024-2034</div>
</td>
</tr>
<tr>
<td>
<div><strong>历史年份</strong></div>
</td>
<td>
<div>2018-2023</div>
</td>
</tr>
<tr>
<td><strong>2024-2034年市场增长率</strong></td>
<td>3.45%</td>
</tr>
</tbody>
</table>

<p style="text-align:justify"><br />
IMARC集团在其最新报告中全面分析了高级胶质瘤市场，该报告题为《高级胶质瘤市场：流行病学、行业趋势、份额、规模、增长、机遇和预测 2024-2034》。高级胶质瘤是指起源于中枢神经系统胶质细胞的恶性肿瘤。该疾病被认为是胶质瘤中最严重和最具侵袭性的形式。其特征是癌细胞迅速分裂、广泛浸润邻近脑组织以及向大脑其他部位扩散的高潜力。该病的症状可能因肿瘤的位置而异，但通常包括头痛、癫痫发作、认知能力下降、性格改变、视力障碍、情绪波动、易怒、抑郁、无力、瘫痪、难以控制肢体运动、身体某些部位感觉丧失等。高级胶质瘤的诊断通常涉及病史回顾和体格检查的结合。神经评估可能被用来评估大脑功能并确定肿瘤对各种神经功能潜在的影响。医疗服务提供者可能还会进行多项诊断研究，如磁共振成像（MRI），以可视化大脑并识别任何异常生长。</p>

<p style="text-align:justify"><img alt="高级胶质瘤市场" src="https://www.imarcgroup.com/CKEditor/ef98a7a6-d783-4285-a8db-e265790bf326high-grade-glioma-market.webp" style="height:450px; width:800px" /></p>

<p style="text-align:justify">遗传突变和遗传性疾病病例的增加，这些疾病通过改变蛋白质的方式导致健康组织癌变，是推动高级胶质瘤市场增长的主要因素。此外，免疫系统功能障碍的日益普遍，导致异常细胞增殖和肿瘤形成，也为市场创造了积极的展望。此外，放射治疗的广泛应用，因为它涉及应用高能X射线以杀死肿瘤或防止疾病进展，进一步推动了市场增长。除此之外，抗血管生成药物如贝伐珠单抗的广泛使用，这些药物针对血管内皮生长因子（VEGF）以抑制异常血管的形成，从而限制肿瘤的营养和氧气供应，也是另一个重要的增长促进因素。此外，立体定向放射外科治疗复发疾病状况的兴起，由于其聚焦输送、非侵入性和治疗持续时间缩短等众多相关益处，预计将在预测期间推动高级胶质瘤市场增长。</p>

<p style="text-align:justify">IMARC集团的新报告对美国、欧盟5国（德国、西班牙、意大利、法国和英国）以及日本的全球高级胶质瘤市场进行了详尽的分析。这包括治疗实践、上市和pipeline药物、个别疗法的市场份额、七个主要市场的市场表现、关键公司的市场表现及其药物的业绩等。该报告还提供了七个主要市场的当前和未来患者群体。根据报告，美国拥有最大的高级胶质瘤患者群体，也是其治疗的最大市场。此外，该报告还提供了当前治疗实践/算法、市场驱动因素、挑战、机遇、报销情景和未满足的医疗需求等。本报告是制造商、投资者、商业策略家、研究人员、顾问以及所有以任何方式涉足或计划进入高级胶质瘤市场的人士必读之作。</p>

<p><strong>研究的时间范围</strong></p>

<ul>
<li>基准年：2023</li>
<li>历史时期：2018-2023</li>
<li>市场预测：2024-2034<br />
&nbsp;</li>
</ul>

<p><strong>涵盖的国家</strong></p>

<ul>
<li>美国</li>
<li>德国</li>
<li>法国</li>
<li>英国</li>
<li>意大利</li>
<li>西班牙</li>
<li>日本<br />
&nbsp;</li>
</ul>

<p><strong>每个国家涵盖的分析</strong></p>

<ul>
<li>历史、当前和未来的流行病学情景</li>
<li>历史、当前和未来的高级胶质瘤市场表现</li>
<li>市场内各种治疗类别的历史、当前和未来表现</li>
<li>高级胶质瘤市场内各种药物的销售额</li>
<li>市场的报销情景</li>
<li>上市和pipeline药物</li>
</ul>

<h4><strong>竞争格局：</strong></h4>

<p>本报告还提供了对当前上市的高级胶质瘤药物和后期pipeline药物的详细分析。</p>

<p><strong>上市药物</strong></p>

<ul>
<li>药物概述</li>
<li>作用机制</li>
<li>监管状况</li>
<li>临床试验结果</li>
<li>药物市场渗透率和市场表现<br />
&nbsp;</li>
</ul>

<p><strong>后期pipeline药物</strong></p>

<ul>
<li>药物概述</li>
<li>作用机制</li>
<li>监管状况</li>
<li>临床试验结果</li>
<li>药物市场渗透率和市场表现<br />
&nbsp;</li>
</ul>

<table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%">
<thead>
<tr>
<th scope="col" style="text-align:left; width:50%"><strong>药物</strong></th>
<th scope="col" style="text-align:left"><strong>公司名称</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gliadel wafer (Carmustine polifeprosan 20 wafer)</td>
<td>Arbor Pharmaceuticals/ Eisai</td>
</tr>
<tr>
<td>Avastin (Bevacizumab)</td>
<td>Genentech/Roche</td>
</tr>
<tr>
<td>Temodar (Temozolomide)</td>
<td>Merck &amp; Co</td>
</tr>
<tr>
<td>BMX001</td>
<td>BioMimetix</td>
</tr>
<tr>
<td>ONC201</td>
<td>Chimerix</td>
</tr>
<tr>
<td>LAM561</td>
<td>Laminar Pharmaceuticals</td>
</tr>
<tr>
<td>OS2966</td>
<td>OncoSynergy</td>
</tr>
<tr>
<td>PTC596</td>
<td>PTC Therapeutic</td>
</tr>
</tbody>
</table>

<p><br />
<strong>*请注意，上表中的药物仅代表上市/pipeline药物的部分列表，完整的列表已在报告中提供。</strong></p>

<h4><strong>本报告解答的关键问题：</strong></h4>

<p><strong>市场洞察</strong></p>

<ul>
<li>高级胶质瘤市场迄今为止的表现如何？未来几年将如何表现？</li>
<li>2023年各种治疗细分市场的市场份额如何？预计到2034年将如何表现？</li>
<li>2023年七个主要市场高级胶质瘤市场的国家规模如何？到2034年将如何变化？</li>
<li>七个主要市场高级胶质瘤市场的增长率如何？未来十年预计将增长多少？</li>
<li>市场中的关键未满足需求是什么？<br />
&nbsp;</li>
</ul>

<p><strong>流行病学洞察</strong></p>

<ul>
<li>2018-2034年七个主要市场高级胶质瘤的现患病例数是多少？</li>
<li>2018-2034年七个主要市场按年龄划分的高级胶质瘤现患病例数是多少？</li>
<li>2018-2034年七个主要市场按性别划分的高级胶质瘤现患病例数是多少？</li>
<li>2018-2034年七个主要市场被诊断出高级胶质瘤的患者数量是多少？</li>
<li>2018-2023年七个主要市场高级胶质瘤患者群体的规模是多少？</li>
<li>2024-2034年七个主要市场的预测患者群体将是多少？</li>
<li>推动高级胶质瘤流行病学趋势的关键因素是什么？</li>
<li>七个主要市场的患者增长率将是多少？<br />
&nbsp;</li>
</ul>

<p><strong>高级胶质瘤：当前治疗情景、上市药物和新兴疗法</strong></p>

<ul>
<li>当前上市药物有哪些？它们的市场表现如何？</li>
<li>关键的pipeline药物有哪些？预计它们在未来的表现将如何？</li>
<li>当前上市药物的安全性如何？它们的疗效如何？</li>
<li>后期pipeline药物的安全性如何？它们的疗效如何？</li>
<li>七个主要市场高级胶质瘤药物的当前治疗指南是什么？</li>
<li>市场中的关键公司有哪些？它们的市场份额是多少？</li>
<li>与高级胶质瘤市场相关的关键并购、许可活动、合作等有哪些？</li>
<li>与高级胶质瘤市场相关的关键监管事件有哪些？</li>
<li>与高级胶质瘤市场相关的临床试验景观在状态方面的结构是什么？</li>
<li>与高级胶质瘤市场相关的临床试验景观在阶段方面的结构是什么？</li>
<li>与高级胶质瘤市场相关的临床试验景观在给药途径方面的结构是什么？</li>
</ul>